Kornimate/medical-research-clean huggingface dataset:
diagnostic performance of controlling nutritional status as a nutritional screening tool in patients with inflammatory bowel disease

Conditions: Inflammatory Bowel Disease 5

Summary: the objective of this observational study is to determine the diagnostic performance of conut as a nutritional screening tool in patients with inflammatory bowel disease. the main questions to be answered are: what is the sensitivity and specificity of conut as a nutritional screening tool in patients with inflammatory bowel disease? the participants will: undergo body composition analysis and a medical history review to understand the characteristics of their current condition, apply the glim criteria, and conduct their nutritional assessment.


Eligibility criteria:
inclusion criteria: * age 18 years and older * gender unspecified * histologically confirmed ulcerative colitis * diagnosis confirmed by a specialist physician exclusion criteria: * patients with any amputation or prosthesis * patients with a pacemaker * patients with any neoplasm * pregnancy or lactation * with comorbidities such as diabetes, hypertension, heart failure, thyroid problems
new non-invasive methods for real-time monitoring of organ function.

Conditions: Acute Renal Failure; Chronic Renal Failure

Summary: measuring novel proteins in the urine of surgical patients that can be used to diagnose impending acute or chronic renal failure.


Eligibility criteria:
inclusion criteria: * patients \> 18 years of age exclusion criteria: * patients at end stage renal disease * patients dependent on dialysis at time of surgery

Keywords: surgical patients
studies with 1,25-dihydroxycholecalciferol

Conditions: Hypocalcemia; Rickets

Summary: vitamin d in the diet undergoes changes in the liver and kidneys to several forms. patients suffering from disorders with vitamin d resistance are unable to absorb calcium from food. patients diagnosed with these disorders will be evaluated and treated with high doses of another form of vitamin d (1,25-dihydroxyvitamin d3). patients will be monitored and observed throughout the study to avoid experiencing side effects from the medication.

patients with extreme resistance to 1,25-dihydroxyvitamin d will be evaluated and treated with high doses of 1,25-dihydroxyvitamin d3. plan: in previously untreated patients the study will be divided into a control and one or more treatment periods. during the control period, parathyroid status will be assessed by parameters nos. 1\& 2 (below). in previously treated patients maintenance vitamin d will be gradually replaced with 1,25(oh)2d3. this will be accomplished by withdrawal of vitamin d and institution of 1,25(oh)2d3 when the serum calcium shows a downward trend. 1,25(oh)2d3 as 0.25 or 0.5 ug capsules (though ind 20,889) or as a solution of i microgram per ml will be administered orally. in most cases, because of consideration of time and expense, the cooperation of the patient's local physician will be enlisted. the following will be monitored: 1. serum calcium, phosphorus,alkaline phosphatase,creatinine at twice weekly intervals. after a maintenance dose has been established, this will be decreased to a monthly, and subsequently 3-6 monthly interval. 2. urine calcium, phosphorus,creatinine and camp before therapy and, when appropriate, during therapy. the dose of 1,25(oh)2d3 will be 0.125 to 50.0 ug/day. serum calcium will not be allowed to rise above the normal range (2.0 -2.4 mm at nih). should hypercalcemia occur, appropriate treatment will be initiated and the drug dosage will be decreased.

Eligibility criteria:
* inclusion criteria: patients with hereditary resistance to calcitrol.

Keywords: calciferol hypocalcemia rickets
clinical trial evaluating the safety and efficacy of moxidectin 2 mg ivermectin-controlled in loa loa microfilaremic patients

Conditions: Onchocerciasis, Ocular; Loiasis

Summary: this study aims at evaluating the safety and efficacy of moxidectin 2 mg in patients with low intensities of microfilariae of loa loa.

this clinical trial will be randomized, double blind, and will compare moxidectin to ivermectin. this study will be conducted in cameroon.

Eligibility criteria:
inclusion criteria: * informed consent written, signed (or with a cross) and dated * men aged 18 to 65 included (women not included in the study) * microfilarial density between 1 and 1,000 mf/ml * body weight ≥ 45 kg and less than 85 kg * good general condition, as determined by the medical questionnaire and clinical examination * hematological parameters and adequate renal and hepatic functions, such as: * leukocytes ≥ 2,800 and ≤ 11,300 cells/ml * hemoglobin ≥ 10.0 g/dl * platelets ≥100,000/mm3 * serum creatinine ≤ 2.5 upper limit (ul) of the laboratory * total bilirubinemia ≤ 2.5 x ul * alat ≤ 2.5 x ul * negative urinary strip: absence of leucocyturia, hematuria, and proteinuria (in case of positivity, a second urinary strip test will be made, for confirmation) exclusion criteria: * participation in any study other than purely observational, in the 4 weeks preceding this study (determined by the theoretical date of administration of mox-2 mg or ivm). * person who has taken ivm in the last 6 months * any vaccination in the 4 weeks preceding this study * acute infection requiring a treatment in the 10 days preceding this study, determined by the anamnesis during the medical interview (example: pulmonary infection, ent, digestive, cutaneous, with implementation of an antibiotic treatment or not) * long-term antiretroviral therapy (protease inhibitor, non-nucleoside reverse transcriptase inhibitor), or treatment with ampicillin or chloramphenicol within 10 days prior to administration of the test drug * history or presence of neurological (including epilepsy) or neuropsychiatric disease * excessive consumption of alcohol or other drug abuse within 72 hours prior to the administration of the test treatment determined by the medical history during the medical interview. * any condition, in the opinion of the investigator, which exposes the subject to an undue risk * subjects who donated blood in the 8 weeks prior to study entry, with a standard volume (\> 500 ml) * known intolerance to ivm, mox or any of the excipients (including placebo) * during the clinical examination: symptoms, physical signs or biological constants suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, cutaneous, immunodeficiency, psychiatric disorders and other abnormalities likely to interfere with the interpretation results of the test. the doctor may then give a favorable or unfavorable opinion for the inclusion of the participant
probiotics improve gastrointestinal symptoms after roux-en-y gastric bypass: a prospective randomized trial

Conditions: Morbid Obesity

Summary: obesity has been a global epidemic. currently, bariatric surgery has been recognized as the only successful treatment for morbid obesity. laparoscopic gastric bypass (lgb) is the leading bariatric surgery worldwide including taiwan, it's resulted in significant weight loss and resolution of metabolic co-morbidities in morbidly obese patients . however, annoyed gastro-intestinal (gi) symptoms are a common complaint after gastric bypass like foul smell flatus, oil flatus and over flatus. the aim of this study was to determine whether probiotics would improve annoyed gi symptoms after gastric bypass. probiotics are live microorganisms (in most cases, bacteria) that are similar to beneficial microorganisms found in the human gut. they are also called "friendly bacteria" or "good bacteria." probiotics are available to consumers mainly in the form of dietary supplements and foods.

probiotics are available in foods and dietary supplements (for example, capsules, tablets, and powders) and in some other forms as well. examples of foods containing probiotics are yogurt, fermented and unfermented milk, miso, and some juices and soy beverages. in probiotic foods and supplements, the bacteria may have been present originally or added during preparation. in this study, we investigate the efficacy of probiotics for alleviating the annoyed gi symptoms after lgb. clostridium butyricum probiotics is a novel microecological feed additive, it has the characteristic of heat tolerance, acid tolerance and antibiotic resistance and is general used to treat the intestinal tract disease in the clinical treatment. its potential function in the situation that feed has been added universally with antibiotics will make it have a good development. this randomized, placebo-controlled, double blind, prospective clinical trial was conducted among 60 patients undergoing gastric bypass for morbid obesity who had annoyed gi symptoms. patients were randomized to the clostridium butyricum miyairi group (80 mg daily , n=20,), bifidobacterium longum bb536 group (2 packs daily, n=20),and biotase group(4 tablets daily, n=20). control group (biotase per day). quality of life was measured and compared by the gastro-intestinal quality of life index (giqli) before and two weeks after in both groups. the higher score means that they have better quality of life. through this study, we hope that we can find a effective probiotics can help all the patient received gastric bypass and bothered by their gastrointestinal problems also can improve their satisfaction of this operation.

Eligibility criteria:
inclusion criteria: * morbid obesity patients after gastric bypass with annoyed intestinal symptoms exclusion criteria: * cannot obey the orders to take medicine

Keywords: food and beverages food dietary supplements
basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes (pinin study)

Conditions: Type 2 Diabetes Mellitus

Summary: pilot study to compare the efficacy and safety of a premixed-insulin regimen (70% intermediate insulin and 30% regular insulin) to a basal-bolus insulin regimen (glargine once daily and glulisine before meals) hospitalized patients with type 2 diabetes.

pilot, randomized, prospective, open-label study admitted to the hospital with a previous diagnosis of type 2 diabetes or with a blood glucose level on admission greater than 180 mg/dl. patients were randomized to receive a premixed human insulin formulation with 70% intermediate insulin plus 30% regular insulin (mixtard 30®, novo nordisk) or a basal-bolus regimen with glargine once daily and glulisine before meals (lantus® and apidra®, sanofi-aventis). the primary outcome of the study was to determine differences in glycemic control between treatment groups as measured by mean daily blood glucose concentration during the hospital stay. secondary objectives were to determine differences in the percentage of glucose measures between 80 and 180 mg/dl, frequency and severity of hypoglycemic events, total daily insulin use, length of hospital stay and glycemic viability between groups.

Eligibility criteria:
inclusion criteria: * previous diagnosis of type 2 diabetes with a blood glucose level on admission greater than 180 mg/dl and treated with diet, any combination of oral antidiabetics agents and/or insulin therapy exclusion criteria: * patients with hyperglycemia without a previous diagnosis of diabetes * patients with acute hyperglycemic emergencies or with severe hyperglycemia treated with intravenous insulin infusion on admission * patients with acute or chronic kidney disease (serum creatinine greater than 2 mg/dl), * patients treated with corticosteroids * patients with history of severe or repeated hypoglycemic episodes * pregnant women * patients expected to require icu admission or less than 3 days of hospital stay

Keywords: type 2 diabetes mellitus treatment hospitalized patients
study of granisetron hydrochloride nasal spray (gns) in healthy volunteers

Conditions: Cancer

Summary: the purpose of this study is to examine the pharmacokinetics (pk), safety and tolerability of 3 intranasal (in) doses (0.5, 1.0 and 2.0 mg) of granisetron hydrochloride nasal sprays (gns) as compared to granisetron iv injection and granisetron tablet in healthy volunteers.


Eligibility criteria:
inclusion criteria: 1. healthy males or females between the ages of 20-64 years 2. body mass index (bmi) of 18.5 (inclusive) to 24 kg/m2; and a total body weight \>45 kg 3. accessible vein for blood sampling 4. no significant abnormalities in electrocardiogram (ecg) recording as per sites' local practice 5. no significant abnormalities in general physical examination as per sites' local practice 6. no significantly abnormal findings in laboratory assessments including hematology, biochemistry and urinalysis as per site's local practice 7. a signed and dated written informed consent must be obtained from the subject prior to study participation 8. capable of understanding and willing to comply with study procedures 9. a negative serum pregnancy test before the first dose of study drug must be available for women of childbearing potential exclusion criteria: 1. females who are pregnant, breast-feeding or have positive pregnancy test 2. history of hypersensitivity to granisetron or its analogs 3. subjects with nasal ulcer, septal perforation, or other nasal conditions that may interfere with nasal administration and determined by the investigator to be ineligible 4. subjects with a qt interval greater than 500 ms or with acute ischemic changes or cardiac abnormality predisposing to arrhythmia on screening electrocardiogram (ecg) or by history 5. evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or other significant disease or clinical findings at screening and determined by the investigator to be ineligible 6. subjects with a history of drug and/or alcohol abuse within 12 months prior to dosing 7. inability to read and/or sign the consent form 8. treatment with any other investigational drug during the 4 weeks prior to the initial dosing for this study 9. subjects who have donated or lost more than 250 ml blood within 2 months prior to the initial dosing for this study 10. male and female subjects with reproductive potential who are not willing to use effective method of contraception. use of hormonal contraceptive is not allowed during the study period 11. clinical significant rhinitis or rhinorrhea at screening determined by the investigator to be ineligible 12. use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to dosing of study medication 13. for subjects who smoke or use tobacco products or are currently using nicotine products (patches, gums, etc.), 2 weeks abstinence is required 14. conditions upon screening which might contraindicate or require that caution be used in the administration of granisetron

Keywords: nausea vomiting chemotherapy radiation therapy
semaglutide effects on cardiovascular outcomes in people with overweight or obesity in the real world

Conditions: Overweight; Obesity; Atherosclerotic Cardiovascular Disease (ASCVD)

Summary: this is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the us, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of cv and other obesity-related clinical outcomes.


Eligibility criteria:
inclusion criteria: 1. participants with overweight or obesity defined as at least one overweight/obesity indication of a specified body mass index (bmi) above or equal to (≥) 27.0 kilogram per meter square (kg/m\^2) and undefined obesity/overweight indications, defined by diagnoses and laboratory values 2. participants with established ascvd defined as a diagnosis of mi, diagnosis of ischemic stroke, and/or evidence of peripheral arterial disease 3. participants who are above or equal to (≥) 45 years old by the end of data availability 4. participants who initiated semaglutide 2.4 mg on or after the eligibility date and june4, 2021 (semaglutide 2.4 mg users) or participants with no evidence of semaglutide 2.4 mg usage (non-users) during january 1, 2016 to december 31, 2023 5. participant with continuous insurance enrolment eligibility above or equal to (≥)12 months prior to the index date 6. participants with re-confirmed overweight/obesity indication during the baseline period exclusion criteria: 1. participants with a diagnosis of chronic or acute pancreatitis 2. participants with a diagnosis of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma 3. participants with end-stage kidney disease (eskd) including chronic or intermittent hemodialysis or peritoneal dialysis, kidney transplant, and/or record of estimate glomerular filtration rate less than (\<) 15 milliliter per minute per 1.73\*meter square (ml/min/1.73m\^2) 4. pregnancy in female participants 5. participants with evidence of diabetes including more or equal to (≥)2 diagnoses of type 1 diabetes or more or equal to ( ≥) 2 diagnoses of type 2 diabetes on distinct dates, use of a glucose-lowering agent, and/or glycated hemoglobin (hba1c) laboratory result above or equal to 6.5 percent (%) 6. use of a glucagon-like peptide-1 (glp-1) or glp-1/gastric inhibitory polypeptide (gip) receptor ago-nist approved for weight management (excluding semaglutide 2.4 mg) 7. participants with evidence of bariatric surgery
focus on reducing dose-limiting toxicities in colon cancer with resistance exercise study

Conditions: Resistance Training; Colon Cancer; Chemotherapy Effect

Summary: force is a randomized home-based resistance training/strength training (rt) intervention study for stage ii and iii colon cancer patients undergoing chemotherapy. participants will be 180 newly diagnosed stage ii and iii colon cancer patients from kaiser permanente of northern california (kpnc), the penn state cancer institute (psci), and the dana farber cancer institute (dfci). the intervention will begin within the first weeks of adjuvant chemotherapy and continue exercise through the completion of post-operative chemotherapy. specifically, the investigators will examine between group differences for rt versus waitlist control for chemotherapy outcomes including dose delays, dose reductions, early stoppage and grade 3 and 4 toxicities. the investigators will also study changes in muscle mass (mm) and changes in specific inflammatory markers (e.g. crp, il-6 and tnf-rii) as potential markers of change in response to rt. to determine effects of change of mm on chemotherapy-specific drug clearance, the investigators will examine the impact body composition changes on the pharmacokinetics (pk) of 5-fu and oxaliplatin, two of the most commonly used drugs for colon cancer.


Eligibility criteria:
inclusion criteria: * men and women ≥18 years * newly diagnosed with histologically confirmed stage ii-ill colon cancer * completed curative-intent surgical resection * currently prescribed one of the following adjuvant chemotherapy regimens: (iv 5-fluorouracil \[5-fu\] / leucovorin \[lv\], capecitabine, folfox \[5-fu, lv, oxaliplatin\], capox \[capecitabine and oxaliplatin\] * patients must have started chemotherapy or plan to start with receipt of the first exercise visit by 3rd infusion visit. patients enrolled at the dana-farber cancer institute and who are receiving folfox chemotherapy are eligible to enroll in the pharmacokinetics sub-study. * no planned major surgery anticipated in the intervention period * sufficient time to heal from any major surgery to start of intervention, including colostomy reversal (port-a-cath removal excluded) * approval by either oncologist or surgeon to participate in trial * readiness as determined by the physical activity readiness questionnaire * ability to understand and the willingness to sign a written informed consent document in english * willingness to be randomized exclusion criteria: * concurrent actively treated other cancer (except non-melanoma skin cancer, in situ cervical cancer or localized prostate cancer treated with surveillance only) * patients with untreated hypertension (\>180 mm hg systolic or \>100 mm hg diastolic) appearing in the patient's medical record in the two weeks prior to screening * presence of metastatic disease * current strength training \>2x week for the past 3 or more months * patients enrolled in other clinical trials of weight loss, physical activity or dietary interventions are ineligible.
emono for the treatment of peripheral neuropathic pain

Conditions: Neuralgia

Summary: to assess the effect of 3 consecutive days of one-hour administration of nitrous oxide/oxygen 50%/50% (emono) versus placebo as oxygen/nitrogen 22%/78% (synthetic medical air), in add-on therapy to chronic analgesic treatments, on average pain intensity in patients with chronic peripheral neuropathic pain. a total of 250 randomised patients to be included in all the participating centres, i.e., 125 randomised patients in each of the 2 study groups treatments


Eligibility criteria:
inclusion criteria: * patients with a mean pain intensity from 4 to 9 as assessed daily with a numerating rating scale during the 7 day period preceding inclusion in spite of administration of usual pain treatments. * neuropathic pain lasting for more than 3 months but less than 10 years * definite or probable peripheral neuropathy exclusion criteria: * legal incapacity * patient with another concomitant chronic pain * ongoing major depression * chemotherapy-induced peripheral neuropathic pain
observational study assessing chronic hepatitis c management in clinical practice in italy (study p05488 am1)

Conditions: Hepatitis C; Hepatitis C, Chronic

Summary: the goal of this study is to elucidate the reasons why patients with chronic hepatitis c (chc) would not be considered eligible for antiviral treatment. the study is conducted in common clinical practice at approximately 54 sites in italy. patients deemed eligible for antiviral therapy will be treated at the discretion of the physician with either peginterferon alfa-2a or peginterferon alfa-2b, both in combination with ribavirin, in accordance with approved labeling. a secondary objective of this study is to define "treatment failure" and to evaluate the reasons for treatment discontinuation.

probability sampling: consecutive adult patients with chronic hepatitis c in clinical practice at approximately 54 sites in italy will be included in the study. the decision as to treatment choice falls at the discretion of the treating physician.

Eligibility criteria:
inclusion criteria: * willingness to sign an informed consent * male and female patients \>=18 years of age with chronic hepatitis c * not previously treated with peg-interferons * positive for serum hepatitis c virus (hcv)-ribonucleic acid (rna) exclusion criteria: * previous treatment with peginterferon * participation in a therapeutic good clinical practice (gcp) clinical study within 30 days prior to study start